Evidence map›Paper›PMID 30077180›Full record

ArticleJournal of nanobiotechnology2018

CD11c-specific bio-nanocapsule enhances vaccine immunogenicity by targeting immune cells.

Hidenori Matsuo, Masaharu Somiya, Masumi Iijima, Takeshi Arakawa, Shun'ichi Kuroda

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Rainbow Trout ErythrocytesFrontiers in immunology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Hidenori MatsuoGraduate School of Bioagricultural Sciences, Nagoya University, Nagoya, 464-8601, Japan.
Masaharu SomiyaDepartment of Biomolecular Science and Reaction, The Institute of Scientific and Industrial Research, Osaka University, Mihogaoka 8-1, Ibaraki, Osaka, 567-0047, Japan.ORCID http://orcid.org/0000-0002-5607-8128
Masumi IijimaGraduate School of Bioagricultural Sciences, Nagoya University, Nagoya, 464-8601, Japan.
Takeshi ArakawaCOMB, Tropical Biosphere Research Center, University of the Ryukyus, Nishihara, Okinawa, 903-0213, Japan.
Shun'ichi KurodaGraduate School of Bioagricultural Sciences, Nagoya University, Nagoya, 464-8601, Japan. skuroda@sanken.osaka-u.ac.jp.
Nagoya University · JPThe University of Osaka · JPTokyo University of Agriculture · JPUniversity of the Ryukyus · JP

Funding

Japan Agency for Medical Research and Development (JP) 17cm0106214h0002Japan Agency for Medical Research and Development (JP) 17fk0310105h0001Japan Society for the Promotion of Science 16H06314Japan Society for the Promotion of Science 17J08534
6 · The paper itself

Abstract

backgroundVarious nanocarriers have been used to deliver subunit vaccines specifically to dendritic cells (DCs) for the improvement of immunogenicity. However, due to their insufficient DC priming ability, these vaccines could not elicit effective innate immunity. We have recently developed a DC-targeting bio-nanocapsule (BNC) by displaying anti-CD11c IgGs via protein A-derived IgG Fc-binding Z domain on the hepatitis B virus envelope L protein particles (α-DC-ZZ-BNC).

resultsAfter the chemical modification with antigens (Ags), the α-DC-ZZ-BNC-Ag complex could deliver Ags to DCs efficiently, leading to effective DC maturation and efficient endosomal escape of Ags, followed by Ag-specific T cell responses and IgG productions. Moreover, the α-DC-ZZ-BNC modified with Japanese encephalitis virus (JEV) envelope-derived D3 Ags could confer protection against 50-fold lethal dose of JEV injection on mice.

conclusionThe α-DC-ZZ-BNC-Ag platform was shown to induce humoral and cellular immunities effectively without any adjuvant.

Indexed as

Immunogenicity, VaccineAnimalsAntigens, ViralCD11c AntigenCell LineDendritic CellsEncephalitis Virus, JapaneseHumansImmunity, CellularImmunoglobulin GJapanese Encephalitis VaccinesMice, Inbred BALB CNanocapsulesOvalbuminParticle SizeStaphylococcal Protein AAntigens, ViralCD11c AntigenImmunoglobulin GJapanese Encephalitis VaccinesL protein, hepatitis B virusNanocapsulesOvalbuminStaphylococcal Protein AViral Envelope ProteinsBio-nanocapsuleDendritic cellHepatitis B virusIn vivo targetingProtective immunityVaccine

Identifiers

PMID30077180
PMCPMC6076409
OpenAlexW2887848987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.